330 related articles for article (PubMed ID: 26432667)
1. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
3. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetics of extramedullary manifestations in multiple myeloma.
Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
[TBL] [Abstract][Full Text] [Related]
5. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
6. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
7. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics.
Bink K; Haralambieva E; Kremer M; Ott G; Beham-Schmid C; de Leval L; Peh SC; Laeng HR; Jütting U; Hutzler P; Quintanilla-Martinez L; Fend F
Haematologica; 2008 Apr; 93(4):623-6. PubMed ID: 18326524
[TBL] [Abstract][Full Text] [Related]
8. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
[TBL] [Abstract][Full Text] [Related]
9. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chromosomal abnormalities by cIg-FISH and association with proliferative and apoptotic indexes in multiple myeloma.
Linardi CC; Martinez G; Velloso ED; Leal AM; Kumeda CA; Buccheri V; Azevedo RS; Peliçario LM; Dorlhiac-Llacer P
Braz J Med Biol Res; 2012 Nov; 45(11):1074-9. PubMed ID: 22911347
[TBL] [Abstract][Full Text] [Related]
11. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
12. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
13. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetics of multiple myeloma.
Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
[TBL] [Abstract][Full Text] [Related]
15. Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence.
Abaza HM; Youssef SR; Saad AA; Kamal GM; Hegazy MG; Ibrahim RI; Annaka LM
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):56-63. PubMed ID: 25929730
[TBL] [Abstract][Full Text] [Related]
16. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
17. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
[TBL] [Abstract][Full Text] [Related]
18. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
[TBL] [Abstract][Full Text] [Related]
19. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.
Dewald GW; Therneau T; Larson D; Lee YK; Fink S; Smoley S; Paternoster S; Adeyinka A; Ketterling R; Van Dyke DL; Fonseca R; Kyle R
Blood; 2005 Nov; 106(10):3553-8. PubMed ID: 16030187
[TBL] [Abstract][Full Text] [Related]
20. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.
Qu X; Chen L; Qiu H; Lu H; Wu H; Qiu H; Liu P; Guo R; Li J
Biomed Res Int; 2015; 2015():787809. PubMed ID: 25984534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
